Diversity action plan requirements, when finalized by FDA, will improve inclusion of communities historically underrepresented in medical research. Washington, DC (March 5, 2024) – Recently members of the Congressional Committee…
Increasing clinical trial diversity has become a top priority for many pharmaceutical companies in recent years. With the FDA soon to finalize guidance on mandated Diversity Action Plans for phase…
Exploring the top 3 reasons that digital therapeutics are desired and the top 3 barriers to access We live in an era of fast-paced innovation to help optimize patient outcomes and…
Education Resources This resource was compiled in partnership with leading patient advocacy partners who participated in Foundation Medicine’s 2023 Patient Advocacy Summit. These organizations have tirelessly contributed to improving the…
As industry and advocacy organizations consider methods for engaging with more diverse, historically inaccessible audiences, consider the possibility of engagement with community health workers (CHWs) and CHW organizations. In recent…
Topline findings from a survey of more than 600 caregivers now available for download.
Learn More